Patents by Inventor Robert M. Stroud

Robert M. Stroud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metal mediated serine protease inhibitors
    Patent number: 6355460
    Abstract: The present invention relates to serine protease inhibitors having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s) and methods for identifying and using the inhibitors. The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and are useful in various processes associated with serine protease isolation and inhibition.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: March 12, 2002
    Assignee: Axys Pharmaceuticals, Inc.
    Inventors: James M. Clark, Kyle Elrod, Thomas E. Jenkins, Bradley A. Katz, William R. Moore, Robert M. Stroud
  • Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
    Patent number: 6255091
    Abstract: A method is presented for determining if the inhibition of metal mediated serine proteases can be potentiated by cobalt or zinc ions.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: July 3, 2001
    Assignees: AXYS Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: James M. Clark, Kyle Elrod, Thomas E. Jenkins, Bradley A. Katz, William R. Moore, Robert M. Stroud
  • Metal complexed serine protease inhibitors
    Patent number: 5925553
    Abstract: Serine protease inhibitors are provided comprising compounds having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s). The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and find use in various processes associated with serine protease isolation and inhibition.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: July 20, 1999
    Assignees: Axys Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: James M. Clark, Thomas E. Jenkins, Bradley A. Katz, Robert M. Stroud
  • Metal complexed serine protease inhibitors
    Patent number: 5900371
    Abstract: Serine protease inhibitors are provided comprising compounds having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s). The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and find use in various processes associated with serine protease isolation and inhibition.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: May 4, 1999
    Assignees: Axys Pharmaceuticals Inc., The Regents of the University of California
    Inventors: James M. Clark, Thomas E. Jenkins, Bradley A. Katz, Robert M. Stroud
  • Metal complexed serine protease inhibitors
    Patent number: 5693515
    Abstract: Serine protease inhibitors are provided comprising compounds having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s). The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and find use in various processes associated with serine protease isolation and inhibition.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 2, 1997
    Assignee: Arris Pharmaceutical Corporation
    Inventors: James M. Clark, Thomas E. Jenkins, Bradley A. Katz, Robert M. Stroud